Guardant Health (NASDAQ:GH) CEO Helmy Eltoukhy Sells 100,000 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Helmy Eltoukhy sold 100,000 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the transaction, the chief executive officer owned 2,012,919 shares of the company’s stock, valued at approximately $254,231,669.70. This represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Guardant Health Price Performance

Guardant Health stock opened at $124.89 on Tuesday. The firm has a 50-day moving average of $100.13 and a 200-day moving average of $101.32. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $134.28. The company has a market cap of $16.56 billion, a price-to-earnings ratio of -36.84 and a beta of 1.61.

Analyst Ratings Changes

GH has been the subject of a number of recent research reports. JPMorgan Chase & Co. increased their price objective on shares of Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Wells Fargo & Company increased their price objective on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Canaccord Genuity Group increased their price objective on shares of Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Robert W. Baird initiated coverage on shares of Guardant Health in a research note on Tuesday, February 17th. They set an “outperform” rating and a $120.00 price objective for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Guardant Health currently has an average rating of “Moderate Buy” and an average price target of $139.80.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. V Square Quantitative Management LLC bought a new position in Guardant Health in the 4th quarter valued at about $27,000. Chesapeake Asset Management LLC bought a new position in Guardant Health in the 4th quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Guardant Health in the 4th quarter valued at about $31,000. Elyxium Wealth LLC bought a new position in Guardant Health in the 4th quarter valued at about $35,000. Finally, Parallel Advisors LLC raised its holdings in Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after acquiring an additional 219 shares during the period. 92.60% of the stock is owned by institutional investors.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.